Nahata M C, Barson W J, Puri S K
College of Pharmacy, Ohio State University, Columbus 43210, USA.
Antimicrob Agents Chemother. 1995 Oct;39(10):2348-9. doi: 10.1128/AAC.39.10.2348.
Cefpirome is a new investigational cephalosporin. We designed a study to determine the pharmacokinetics and tolerance of cefpirome in pediatric patients. A single dose of cefpirome was administered intravenously over 15 min to 18 patients (age 0.5 to 18 years). The doses were 10 mg/kg of body weight for five patients, 25 mg/kg of body weight for seven patients, and 50 mg/kg of body weight for six patients. Blood samples were collected at 0, 0.25, 0.5, 1, 3, 5, and 8 h after the dose, and cefpirome was measured by a high-performance liquid chromatography method. The maximum concentration in serum ranged from about 53.6 to 454 micrograms/ml after doses of 10 to 50 mg/kg. The total body clearance, apparent volume of distribution, and elimination half-life were 2.15 +/- 0.70 ml/min/kg, 0.32 +/- 0.32 liter/kg, and 1.8 +/- 1.3 h, respectively. No significant adverse effects were attributed to cefpirome. These data may be useful in conducting efficacy and safety studies of cefpirome in pediatric patients.
头孢匹罗是一种新型的研究用头孢菌素。我们设计了一项研究来确定头孢匹罗在儿科患者中的药代动力学和耐受性。对18名患者（年龄0.5至18岁）静脉注射单剂量头孢匹罗，注射时间为15分钟。其中5名患者的剂量为10毫克/千克体重，7名患者为25毫克/千克体重，6名患者为50毫克/千克体重。在给药后0、0.25、0.5、1、3、5和8小时采集血样，采用高效液相色谱法测定头孢匹罗。剂量为10至50毫克/千克体重后，血清中的最大浓度范围约为53.6至454微克/毫升。总体清除率、表观分布容积和消除半衰期分别为2.15±0.70毫升/分钟/千克、0.32±0.32升/千克和1.8±1.3小时。未发现头孢匹罗有明显的不良反应。这些数据可能有助于开展头孢匹罗在儿科患者中的疗效和安全性研究。
